Predict your next investment

HEALTHCARE | Drug Delivery
clearsidebio.com

See what CB Insights has to offer

Stage

Loan | IPO

Total Raised

$51.58M

Market Cap

0.22B

Stock Price

3.67

Revenue

$0000 

About Clearside Biomedical

Clearside Biomedical, headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside's proprietary microinjector to reach diseased tissue through the SCS. Clearside holds intellectual property protecting the delivery of drugs of any type through the SCS to reach the back of the eye.

Clearside Biomedical Headquarter Location

900 North Point Pkwy Suite 200

Alpharetta, Georgia, 30005,

United States

678-270-3631

Latest Clearside Biomedical News

Is the development of exudative AMD when inhibiting complement in GA a concern?

Nov 17, 2021

Disclosures: Eichenbaum reports being a consultant and speaker for Apellis and an investigator for Iveric bio and NGM Biopharmaceuticals. Holekamp reports consulting for Adverum, Allergan, Annexon, Apellis, Bayer, Clearside Biomedical, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Katalyst Surgical, Lineage Cell Therapeutics, Nacuity, Notal Vision, Novartis, PolyActiva, Regeneron and Stealth Biosciences. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio The risk is not worth the reward Dealing with new-onset macular exudation while treating geographic atrophy with the complement inhibitors currently undergoing investigation seems a risk not worth the reward. David E. Eichenbaum Based on the best available data we have from Apellis, the treatment effect of APL-2 (pegcetacoplan) is not profound. We have an average of less than a 20% reduction in geographic atrophy (GA) lesion growth as a primary endpoint when the data from both trials are pooled. This means that we would be treating patients with high frequency injections every 4 to 8 weeks in exchange for a small clinical benefit, while exposing them to the risk of developing macular exudation. And if this happens, these patients would have to go on to a second high-burden treatment while they are receiving already one high-burden treatment that does not have a profound clinical benefit. That is the problem: Is the whole process really worth it? If we look at the subgroup of patients with extrafoveal lesions, the reduction in the rate of lesion growth increases to 25%, a similar rate to what was achieved in the same population with Zimura (avacincaptad pegol, Iveric bio) in the GATHER1 trial. Whether the same degree of efficacy will be confirmed in GATHER2 is yet to be seen, but even then, is the 25% effect in these patients with exclusively extrafoveal GA lesions profound enough to warrant exposing them to the risk of increased macular exudation? I do not think we have a clear answer on that. My concern is that patients are going to receive multiple injections, suffer disease advancement and have an increased risk for exudation requiring treatment. There are a variety of other complement therapies currently in trial that may not hold this risk, such as NGM621 (NGM Biopharmaceuticals), a monoclonal antibody that is another way of potentially inhibiting complement C3. It may be that the pegylation of Zimura and APL-2 is what induces the neovascularization. Even if we do see the biological effect from this class of drugs, these agent may not be the right avenue to start with because we have potentially better options right around the corner. David E. Eichenbaum, MD, is from Retina Vitreous Associates of Florida in Saint Petersburg, Florida. Exudative AMD can be successfully treated In the near future, treatment of GA may involve the inhibition of the complement cascade. At present, inhibitors of C3 and C5 appear to be on the brink of pivotal clinical trial evidence that could lead to FDA and EMA approval. In the clinical trials of the two agents, pegcetacoplan and avacincaptad pegol, for which data have been released so far, there is a safety signal that treated eyes experience a higher rate of exudative AMD. This, however, does not concern me. Nancy M. Holekamp First of all, I consider it a positive biologic signal that these two investigational therapies are having an effect on the complement system, therefore altering the disease state we know as GA in age-related macular degeneration. We did not see any such signal in the failed trials of lampalizumab. Furthermore, this safety signal is dose related. In the DERBY and OAKS phase 3 clinical trials, the combined rates of exudative AMD across the studies were 6% in the monthly dose group, 4.1% in the every other month dose group and 2.4% in the sham group. If we include the cases not reported by the investigators but detected by the reading center, the rates were 6.4%, 5%, and 3.8%, respectively. Secondly, the rates in DERBY and OAKS were lower than those seen in the FILLY phase 2 trial at 20.9% in the monthly dose group and 8.9% in the every other month dose group. Phase 3 clinical trials allow us to better characterize this emergent exudative AMD, potentially assisting future management strategies. Patients with fellow-eye choroidal neovascularization were included, and this is a well-known risk factor. All cases with available fluorescein angiography showed occult macular neovascularization except for two classical cases in DERBY. Double-layer signs were also a risk factor. Affected patients were treated with anti-VEGF injections while continuing to receive the study medication according to their randomized arm, and no loss of visual acuity attributed to the exudation was reported. In my practice, I am successfully treating exudative AMD only to watch my patients lose vision over time to GA. I welcome the opportunity to preserve vision in my patients with AMD even if it means giving injections for both forms of advanced AMD. Nancy M. Holekamp, MD, is from Pepose Vision Institute in St. Louis. Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Clearside Biomedical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Clearside Biomedical is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Clearside Biomedical Patents

Clearside Biomedical has filed 40 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/11/2017

4/13/2021

Diseases of the eye and adnexa, Drug delivery devices, Medical equipment, Dosage forms, Ophthalmology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/11/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/13/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Diseases of the eye and adnexa, Drug delivery devices, Medical equipment, Dosage forms, Ophthalmology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Clearside Biomedical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Clearside Biomedical Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.